March 2025 • PharmaTimes Magazine • 4-5


Contents


Features

Why the new public health ecosystem matters to pharma


The challenge of targeting chronic inflammation in obesity


Making accurate science stand out amid the information explosion


Future of biopharma – key operational shifts to watch this year


Why early cancer detection for everyone may not be desirable


Analysis

Medication non-adherence is not only dangerous but expensive


Unlikely healthcare innovation may yet be the ultimate machine


How effective digital design can streamline regulatory approval


Unravelling the various mysteries of neurological conditions


Safeguarding concerns as the era of Wegovy looms large


SmartPeople

16.
Dual intentions
Pharma’s curiously difficult relationship with demonstrating ambition


26.
People have spoken
The challenges of patient recruitment across a changing environment


28.
Learning to make cocktails
Pharma’s Chris Henry learns he has Parkinson’s disease


36.
Moving with the times
Who has gone, who is going and who will be meeting them on arrival


0